Trial Profile
Open, randomized, controlled, multicenter phase III study comparing 5FU/ FA [fluorouracil + folinic acid] plus irinotecan (FOLFIRI) plus cetuximab [Erbitux; Merck] versus 5FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Dec 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CRYSTAL
- Sponsors Merck KGaA
- 05 Oct 2021 Planned number of patients changed from 1080 to 1300.
- 02 Mar 2017 According to a Merck KGaA media release, based on the data from this and other three studies (CTP: 15696, 37756 and 60760) the UK National Institute for Health and Care Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with either FOLFIRI or FOLFOX as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC).
- 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research